Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Next Generation Of PFO Closure Systems Aim For Less Device Exposure

This article was originally published in The Gray Sheet

Executive Summary

Firms are looking ahead to next-generation patent foramen ovale closure devices that leave less of a "footprint" than the standard implant

You may also be interested in...



With Limited Near-Term PFO Closure Prospects In U.S., NMT Looks To Europe

NMT Medical is banking on strong market growth in Europe to counteract stagnant U.S. performance

With Limited Near-Term PFO Closure Prospects In U.S., NMT Looks To Europe

NMT Medical is banking on strong market growth in Europe to counteract stagnant U.S. performance

NMT Medical Hopes To Avoid Another Headache In Modified Migraine Trial

NMT Medical will move forward with its planned PFO closure migraine study under a new trial design cleared recently by FDA, the firm announced Aug. 31

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024137

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel